Tarsus Pharmaceuticals completed its Acquisition of Alkeus on September 4, 2026, paying $270,000,000 in cash and issuing 2,908,692 common shares. The transaction also includes potential milestone payments up to $350,000,000 and low-to-mid single-digit Revenue sharing on future worldwide net sales, giving investors defined contingent obligations tied to approval and sales.
Key Highlights
- Tarsus Pharmaceuticals completed its acquisition of Alkeus on September 4, 2026.
- Tarsus paid $270,000,000 in up-front cash and issued 2,908,692 common shares to Alkeus equityholders.
- Milestone payments can reach an aggregate $350,000,000, with $250,000,000 linked to U.S. regulatory approval and $100,000,000 to the first U.S. sale.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) completed its acquisition of Alkeus Pharmaceuticals, Inc. on September 4, 2026, paying $270,000,000 in up-front cash consideration. The company also issued 2,908,692 shares of common stock to Alkeus equityholders.
Alkeus Joins Tarsus Structure
A wholly owned Tarsus Subsidiary merged with Alkeus, with Alkeus continuing as the surviving entity. The transaction was completed under the Merger agreement dated July 31, 2026, between Tarsus Pharmaceuticals, Alkeus, the subsidiary and Shareholder Representative Services LLC in its capacity as securityholders’ representative. Tarsus delivered the up-front cash and common-stock consideration to Alkeus equityholders upon completion of the acquisition.
Milestones Reach $350M
The agreement includes milestone payments of up to an aggregate $350,000,000. A further $100,000,000 is payable in cash when an Alkeus product is first sold in the United States. Those payments are separate from the up-front consideration delivered at closing.
Revenue Sharing Tied To Sales
The payments are subject to certain reductions. The completed acquisition therefore includes up-front cash and stock consideration, potential milestone payments tied to U.S. regulatory approval and sales, and future revenue-sharing obligations tied to worldwide product revenue.



Please wait processing your request...